KIMS RENOVA Oncology Institute Inaugurated at KIMS Hospitals, Bengaluru

IMT News Desk
IMT News Desk
· 3 min read
KIMS Hospitals Bengaluru inaugurates KIMS RENOVA Oncology Institute, expanding advanced, multidisciplinary cancer care and screening.

KIMS Hospitals, Mahadevapura, Bengaluru, has inaugurated the KIMS RENOVA Oncology Institute, a comprehensive cancer care centre designed to deliver advanced, integrated, and patient-centric oncology services.

Along with Samrohana Cancer Foundation, the institute also announced the “134 Free Screening Camp Pledge”, inspired by the legacy of former India cricketer Mr. VVS Laxman, who represented the country in 134 Test matches. Under the initiative, 134 free awareness and screening camps will be conducted for underserved communities, with a focus on prevention, awareness, and early diagnosis in the fight against cancer.

The inauguration also featured a fireside chat with Mr. VVS Laxman and senior experts from KIMS Hospitals, adding a community-focused element to the launch.

The KIMS RENOVA Oncology Institute, in association with KIMS MACS OncoSurgery, has been positioned as a comprehensive oncology ecosystem bringing together expertise in surgical oncology, robotic surgery, medical oncology, and multidisciplinary cancer care. The collaboration is aimed at strengthening KIMS Hospitals’ focus on advanced diagnosis, precision treatment, and holistic support for cancer patients.

Commenting on the launch, Dr. B. Bhaskar Rao, Chairman and Managing Director, KIMS Group of Hospitals, said, “Our strategy is to scale our footprint and ensure world-class healthcare is accessible to everyone, integrating clinical precision with genuine patient care. The inauguration of the KIMS RENOVA Oncology Institute in Mahadevapura, Bengaluru, marks a new milestone in this journey. By bringing together advanced oncological technology and renowned medical experts, we are setting a benchmark in cancer care.”

Speaking on the occasion, Dr. Nitish Shetty, Managing Director, KIMS Hospitals (Krishna Institute of Medical Sciences), Bengaluru, said, “The launch of KIMS RENOVA Oncology Institute is a significant step towards our vision of bringing world-class, comprehensive cancer care closer to patients. Through this collaboration, we are combining KIMS Hospitals’ clinical expertise and healthcare infrastructure with RENOVA’s focused oncology excellence and KIMS MACS Onco Surgery’s surgical oncology capabilities to create a centre that delivers advanced treatment with compassion and precision.”

Dr. Sandeep Nayak, Chairman, Oncology & Executive Director, Surgical Oncology & Robotic Surgery, KIMS Hospitals (Krishna Institute of Medical Sciences), Bengaluru, said, “Cancer treatment today requires precision, collaboration and expertise across multiple disciplines. Through KIMS RENOVA Oncology Institute and KIMS MACS Onco Surgery, we are bringing together advanced surgical techniques, robotic surgery, medical oncology, and comprehensive cancer management to provide personalised care pathways for every patient.”

Mr. Sridhar Peddireddy, Founder & CEO, Renova Hospitals, said, “Our association with KIMS Hospitals represents a shared vision of transforming oncology care. By combining RENOVA’s specialised oncology expertise with KIMS Hospitals’ strong clinical ecosystem and KIMS MACS Onco Surgery’s excellence in surgical oncology, we aim to deliver accessible, advanced, and compassionate cancer care.”

KIMS RENOVA Oncology Institute is expected to offer a complete spectrum of cancer services, including prevention, screening, diagnosis, medical oncology, surgical oncology, robotic surgery, and supportive care through a coordinated multidisciplinary model.

Read Next

PM Modi to Dedicate Key Healthcare Infrastructure Projects to Nation on July 17: PGIMER Director
News
July 14, 2026

PM Modi to Dedicate Key Healthcare Infrastructure Projects to Nation on July 17: PGIMER Director

Prime Minister Narendra Modi will dedicate several key healthcare infrastructure projects to the nation on July 17, according to PGIMER Director Dr Vivek Lal. The projects include the Advanced Mother and Child Centre, the Advanced Neurosciences Centre and a new Critical Care Block, all of which are expected to strengthen tertiary care services and expand […]
Article by: IMT News Desk
OneSource Specialty Pharma and Formycon AG Announce Strategic Manufacturing Partnership for Biosimilars
News
July 14, 2026

OneSource Specialty Pharma and Formycon AG Announce Strategic Manufacturing Partnership for Biosimilars

OneSource Specialty Pharma Limited and Formycon AG have announced a strategic manufacturing partnership for biosimilars, bringing together Formycon’s biosimilar development expertise and OneSource’s integrated biologics manufacturing capabilities to support global markets. Under the agreement, OneSource will serve as a strategic manufacturing partner for Formycon and provide both drug substance and drug product manufacturing from its […]
Article by: IMT News Desk
FDA Approves At-Home Starter Dose of Eisai-Biogen’s Alzheimer’s Drug Leqembi
News
July 14, 2026

FDA Approves At-Home Starter Dose of Eisai-Biogen’s Alzheimer’s Drug Leqembi

The U.S. Food and Drug Administration has approved an at-home starting dose of Eisai and Biogen’s Alzheimer’s drug Leqembi, allowing some patients to begin treatment with injections administered by themselves or a caregiver. The decision expands access to the drug’s subcutaneous formulation, which can now be used as a starter dose rather than only after […]
Article by: IMT News Desk
Emcure Pharmaceuticals Consolidates Full Ownership of Gennova Amid Leadership Transition
News
July 14, 2026

Emcure Pharmaceuticals Consolidates Full Ownership of Gennova Amid Leadership Transition

Emcure Pharmaceuticals Limited has announced the consolidation of its shareholding in biopharma subsidiary Gennova Biopharmaceuticals Limited, alongside a leadership transition, as it sharpens its focus on biologics and biosimilars. The company is acquiring the entire 12.05% minority stake in Gennova held by Dr Sanjay Singh and others, taking its ownership to 100% and making Gennova […]
Article by: IMT News Desk